Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM

Inclusion Criteria

• •Criteria for Inclusion:
• •Male or female patients of ≥18 years of age.
• •Patients with documented histologic diagnosis of glioblastoma multiforme (newly diagnosed)
• •Patients must have at least one confirmed and evaluable tumor site.∗
• •\*A confirmed tumor site is one which is biopsy-proven. NOTE: Radiographic procedures (e.g., Gd-enhanced MRI or CT scans) documenting existing lesions must have been performed within three weeks of treatment on this research study.
• •Patients must have a Karnofsky performance status ≥70% (or the equivalent ECOG level of 0-2) and an expected survival of ≥ three months.
• •Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study.
• •Criteria for Exclusion:
• •Previous treatment with Bevacizumab.
• •Women who are pregnant or lactating.
• •Women of childbearing potential and fertile men who decline to use effective contraception during and for a period of three months after the treatment period.
• •Patients with significant intercurrent medical or psychiatric conditions that would place them at increased risk or affect their ability to receive or comply with treatment or post-treatment clinical monitoring.